Internalization of Bacillus intermedius ribonuclease (BINASE) induces human alveolar adenocarcinoma cell death

Hector Alejandro Cabrera-Fuentes1, Muhammad Aslam, Mona Saffarzadeh

  • 1Department of Microbiology, Kazan Federal University, Kremlevskaya Str. 18, 420008 Kazan, Republic of Tatarstan, Russian Federation. Hector.A.Cabrera-Fuentes@biochemie.med.uni-giessen.de

Insights

Binase, an anticancer enzyme, selectively triggers apoptosis in human lung cancer cells while sparing normal cells. This novel approach offers a promising alternative to traditional DNA-damaging cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Ribonuclease (RNase) therapy presents a novel, non-DNA damaging approach to anticancer treatment.
  • Certain RNases exhibit cytotoxic effects, showing potential for selective malignancy treatment.
  • Binase, an RNase from Bacillus intermedius, has demonstrated promising anticancer activity.

Purpose of the Study:

  • To investigate the selective cytotoxicity of Binase against human A549 alveolar adenocarcinoma cells.
  • To elucidate the time-dependent molecular mechanisms of Binase-induced apoptosis in cancer cells.
  • To assess the differential effect of Binase on cancer cells versus normal lung epithelial cells.

Main Methods:

  • Treatment of A549 and LEK cells with Binase.
  • Time-course analysis of Binase internalization, cellular permeability, and apoptotic markers.
  • Assessment of DNA fragmentation and cell death.

Main Results:

  • Binase selectively induced apoptosis in A549 cells, with no effect on normal LEK cells.
  • Observed time-dependent Binase internalization within 2 hours.
  • Detected increased macromolecular permeability (4-6 hours), apoptosis (24 hours), and cell death (72 hours).

Conclusions:

  • Binase demonstrates selective toxicity towards lung adenocarcinoma cells, highlighting its potential as a targeted anticancer agent.
  • Understanding Binase's molecular mechanisms provides insights for developing novel RNase-based cancer therapeutics.
  • Tumor transformation confers sensitivity to Binase, suggesting a basis for its selective action.